EGFR and exanthem: However, skin rash as an adverse event of EGFR-TKIs did not significantly influence the treatment efficacy of first-line EGFR-TKIs (PFS HR 0.86 [95% CI 0.54–1.35], p = 0.51; OS HR 0.73 [95% CI 0.40–1.33], p = 0.30).